Company news

Inhibrx Biosciences, Inc. news in 2025

Inhibrx Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

December 16, 2025

Inhibrx Reports Third Quarter 2025 Financial Results

November 14, 2025

Inhibrx Announces Participation in Upcoming Scientific Conferences

November 4, 2025

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

October 23, 2025

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

October 22, 2025

Inhibrx Reports Second Quarter 2025 Financial Results

August 13, 2025

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

April 1, 2025

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

March 17, 2025

Decks in 2025